Dizal’s Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting
Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presentations SHANGHAI, April 27, 2023 /PRNewswire/ -- Dizal today announced that multiple clinical data of its two leading assets – sunvozertinib and golidocitinib have been selected for presentations at the 2023 ASCO, June 2-6, 2023 in Chicago. A total of four abstracts will be presented, including two oral...
YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in eight participants, including six patients with ATTR amyloidosis with polyneuropathy (ATTR-PN) and two patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), across two...
First eye drops registered on the Australian Register of Therapeutic Goods (ARTG) to slow the progression of short-sightedness now available for children aged from 4 to 14 years old[1]
SYDNEY, March 17, 2022 /PRNewswire/ -- Aspen announced the Therapeutic Goods Administration (TGA) listing of a new medication to slow the progression of short-sightedness (myopia) in children and young teenagers. EIKANCE® 0.01% eye drops (atropine sulfate monohydrate 0.01%) are available on prescription for children aged 4 to 14 years, as a treatment to slow the progression of myopia and...
Fosun Pharma Announces 2025 Interim Results
Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its operating performance for the first half of 2025 ("the Reporting Period"). During the Reporting Period, Fosun Pharma continued to push...
Late-Breaking Abstract! Alphamab Oncology Presented the Latest Clinical Data of Anti-HER2 bispecific ADC Subcutaneous Co-formulation JSKN033 at SITC 2024
SUZHOU, China, Nov. 11, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the results of the first-in-human clinical study of JSKN033, a high-concentration subcutaneous co-formulation consisting of anti-HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immune checkpoint inhibitor, were presented for the first time as a poster in the Late-Breaking Abstract (LBA) session at the 39th Annual Meeting...
Anti-Aging and Reproductive Medical Giants Gathered in Hong Kong Dragon’s Medical Led Chinese Medical Development
HONG KONG, June 9, 2023 /PRNewswire/ -- Dragon's Medical successfully held its Advance Medical Technology Press Conference 2023 at W Hong Kong today, signing strategic partnership agreements with various medical groups from Mainland China, Hong Kong and Taiwan, deepening their long-term strategic partnership. At the event, Dragon's Medical announced the launch of...
Juncell Therapeutics Opens State-of-the-Art Facility for TIL Production
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand opening of its state-of-the-art TIL manufacturing facility located at Anting International Medical Industry Park in Jiading District, Shanghai, China. This facility has the largest capacity and was constructed in compliance with the...
HaemaLogiX Announces Appointment of Damian Clarke-Bruce as Managing Director and CEO
SYDNEY, Nov. 14, 2023 /PRNewswire/ -- HaemaLogiX Ltd, a clinical stage Australian biotech, is pleased to announce the appointment of Damian Clarke-Bruce as Managing Director and CEO, effective 13 November 2023. Outgoing CEO Bryce Carmine will remain active in the company, retaining his role as Chair. "I'm immensely proud to have served as HaemaLogiX's CEO for the past 8...
Neurizon Files IND Application to Support HEALEY ALS Platform Trial
Highlights: IND application submission to the U.S. Food and Drug Administration (FDA) is a pivotal step in initiating a Phase 2/3 clinical study for NUZ-001 The IND is a comprehensive dossier of information, including animal and human studies, pharmacokinetic analyses, toxicology studies, and manufacturing information for NUZ-001 The FDA has a...
Always on Alert for Balance Loss with “The Balance Assessment Device,” An Outstanding Innovation by Chula Researcher
Chula Engineering lecturer's innovation "The Balance Assessment Device"—gold medal winner at ITEX 2023, Malaysia, and recipient of World Invention Intellectual Property Associations' (WIIPA) Special Award (Gold Medal)—checks body balance and balance loss for behavior changes and fall prevention to promote fall risk awareness and knowledge. BANGKOK, Nov. 15, 2023 /PRNewswire/ -- Standing in public buses, Chatchanee Pakavatsoontorn, an adjunct lecturer...
